20130300.LumB
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.410
- E2F_TARGETS+0.310
- MYC_TARGETS_V2+0.220
- DNA_REPAIR+0.190
- ESTROGEN_RESPONSE_EARLY+0.180
- ESTROGEN_RESPONSE_LATE+0.160
- MYC_TARGETS_V1+0.160
- G2M_CHECKPOINT+0.110
- OXIDATIVE_PHOSPHORYLATION+0.110
- PANCREAS_BETA_CELLS+0.110
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- COAGULATION-0.380
- ALLOGRAFT_REJECTION-0.340
- NOTCH_SIGNALING-0.340
- WNT_BETA_CATENIN_SIGNALING-0.340
- APICAL_JUNCTION-0.310
- COMPLEMENT-0.310
- ANDROGEN_RESPONSE-0.290
- APICAL_SURFACE-0.270
- INFLAMMATORY_RESPONSE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-C8-A1HO-01A-11R-A13Q-07 | — | B | 0.865 |
| 2 | MBCProject_0076_T1_RNA | — | B | 0.843 |
| 3 | TCGA-AO-A03P-01A-11R-A00Z-07 | — | B | 0.826 |
| 4 | TCGA-A8-A06N-01A-11R-A00Z-07 | — | B | 0.820 |
| 5 | SRR8518412 | — | B | 0.819 |
| 6 | TCGA-E7-A6ME-01A-22R-A32O-07 | — | — | 0.817 |
| 7 | TCGA-BA-A6DE-01A-22R-A31N-07 | — | — | 0.813 |
| 8 | TCGA-A2-A0ET-01A-31R-A034-07 | — | B | 0.803 |
| 9 | TCGA-AC-A7VB-01A-11R-A352-07 | — | B | 0.799 |
| 10 | TCGA-AO-A0J3-01A-11R-A034-07 | — | B | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.220 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.110 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.110 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.080 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |